Form 485BPOS LAZARD RETIREMENT SERIES
Securities Act
File No. 333-22309
Investment Company Act File No. 811-08071
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-1A
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 |
/X/ | |
Post-Effective Amendment No. 79 |
/X/ | |
and |
||
REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 |
/X/ | |
Amendment No. 79 |
/X/ | |
(Check appropriate box or boxes) |
| |
| LAZARD RETIREMENT SERIES, INC. |
||
(Exact Name of Registrant as Specified in Charter) |
||
(212) 632-6000 |
||
(Registrant's Telephone Number, including Area Code) |
||
30 Rockefeller Plaza, New York, New York 10112 |
||
(Address of Principal Executive: Number, Street, City, State, Zip Code) |
||
Mark R. Anderson, Esq. |
||
Copy to: |
||
It is proposed that this filing will become effective (check appropriate box) |
| X | immediately upon filing pursuant to paragraph (b) | |
| on (DATE) pursuant to paragraph (b) | ||
| 60 days after filing pursuant to paragraph (a)(1) | ||
| on (DATE) pursuant to paragraph (a)(1) | ||
| 75 days after filing pursuant to paragraph (a)(2) | ||
| on (DATE) pursuant to paragraph (a)(2) of Rule 485. | ||
| If appropriate, check the following box: | ||
| this post-effective amendment designates a new effective date for a previously filed post-effective amendment. | ||
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933 and the Investment Company Act of 1940, the Registrant certifies that it meets all of the requirements for effectiveness of this Amendment to the Registration Statement under Rule 485(b) of the Securities Act of 1933 and has duly caused this Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, and State of New York, on the 18th day of May, 2018.
LAZARD RETIREMENT SERIES, INC. | ||
By: |
/s/ Nathan A. Paul* | |
Nathan A. Paul, Chief Executive Officer | ||
Pursuant to the requirements of the Securities Act of 1933, this Amendment to Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.
|
/s/ Nathan A. Paul* Nathan A. Paul |
President | May 18, 2018 |
| /s/ Christopher Snively* Christopher Snively |
Chief Financial Officer | May 18, 2018 |
|
/s/ Ashish Bhutani* Ashish Bhutani |
Director | May 18, 2018 |
|
/s/ Franci J. Blassberg* Franci J. Blassberg |
Director | May 18, 2018 |
| /s/ Kenneth S. Davidson* Kenneth S. Davidson |
Director | May 18, 2018 |
|
/s/ Nancy A. Eckl* Nancy A. Eckl |
Director | May 18, 2018 |
|
/s/ Trevor W. Morrison* Trevor W. Morrison |
Director | May 18, 2018 |
|
/s/ Richard Reiss, Jr.* Richard Reiss, Jr. |
Director | May 18, 2018 |
| /s/ Robert M. Solmson* Robert M. Solmson |
Director | May 18, 2018 |
|
*By: /s/ Mark R. Anderson Attorney-in-fact, Mark R. Anderson |
||
EXHIBIT INDEX
| Exhibit No. | Description |
| EX-101.INS | XBRL Instance Document |
| EX-101.SCH | XBRL Taxonomy Extension Schema Document |
| EX-101.DEF | XBRL Taxonomy Extension Definition Linkbase |
| EX-101.LAB | XBRL Taxonomy Extension Labels Linkbase |
| EX-101.PRE | XBRL Taxonomy Extension Presentation Linkbase |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zymeworks to acquire Theravance Biopharma for $17 per share
- Zymeworks to buy Theravance Biopharma for $17 per share
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share